Navigation Links
Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Date:9/5/2007

NicVAX Supports Statistically Significant Point Prevalence and Continuous Abstinence by Dose, Schedule and Antibody Response; Nabi to Host Conference

Call Today

BOCA RATON, Fla., Sept. 5 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced nine-month data from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. These nine-month data demonstrate NicVAX efficacy in supporting statistically significant and continuous abstinence rates by dose as well as by antibody response. The nine-month data also have enabled Nabi to determine what it believes is the most effective dose and schedule for NicVAX and determine the antibody concentration threshold for clinical efficacy. In May 2007, Nabi announced this trial's six-month data -- a statistically significant number of patients with a high anti-nicotine antibody response met the trial's primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

NicVAX Nine-Month Data Key Findings

-- High antibody responders (top 30%) continued to show statistically

significant abstinence at nine months:

-- 9-Month continuous abstinence rate: NicVAX=20% (12/61, p=0.0076) vs.

Placebo=6% (6/100)

-- Statistically significant dose response observed for continuous

abstinence at six and nine months for Schedule 2, 200 and 400 microgram

doses in the intent to treat population:

-- 9-Month continuous abstinence: NicVAX 400 micrograms =18% (9/51,

p=0.0047), Placebo=4% (4/100)

-- 9-
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... 2014 InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) ... revolutionizing spinal cord injury (SCI) treatment with their novel ... in tissue regrowth in the spinal cord area when ... FDA approved polymer, the scaffold ultimately breaks down to ... human body. NVIV has recently attracted significant investor attention ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... while working for NBC News in Liberia has cleared ... unit at Nebraska Medical Center in Omaha, where he had been ... A blood test confirmed by the U.S. Centers for Disease Control ... Providence, R.I., NBC News reported Tuesday night. "Recovering ...
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... of Cost-Effective High-Quality Home Infusion Can be ... WASHINGTON, March 5 Patients on Medicare ... Johnny Isakson (R-GA) and Representative Eliot L. ... a flaw in the Medicare program which ...
... YORK (March 5, 2009) -- Two highly lethal viruses that ... established drug used to prevent and treat malaria, according to ... Medical College in the Journal of Virology . Due ... advance of the first April print issue. , The two ...
... of Nutrition and Physical Activity at the Indiana State ... GoTrybe.com to provide Indiana kids and teens with a ... fun. Young Hoosiers can enjoy FREE memberships to the ... www.GoTrybeIN.com . A 2007 Youth Risk Behavior Survey showed ...
... the commercial printing superstore was honored for ecommerce expertise when President ... the online version of the highly respected Entrepreneur magazine. , ... ... selected Mr. Del Chiaro for the interview based on his proven ...
... on annual listOAKLAND, Calif., March 5 ... been recognized by DiversityMBA ... was ranked No. 1 in the publication,s fourth annual ... Diverse Managers to Work," which will hit newsstands in ...
... don,t offer emergency contraception pills to adolescents who ... because of misinformation about how the medicine works, ... of Philadelphia. Improved physician education may increase prescription ... said. Researchers surveyed 291 members of the ...
Cached Medicine News:Health News:Patients, Senate, House Members Identify Significant Medicare Savings While Increasing Quality of Patient Care 2Health News:Patients, Senate, House Members Identify Significant Medicare Savings While Increasing Quality of Patient Care 3Health News:Drug blocks 2 of world's deadliest emerging viruses 2Health News:Drug blocks 2 of world's deadliest emerging viruses 3Health News:GoTrybe.com Launched in Indiana to Promote Children's Health 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 3Health News:Research Says Better Physician Education Would Improve Hospital Prescription of Emergency Birth Control to Teens 2Health News:Research Says Better Physician Education Would Improve Hospital Prescription of Emergency Birth Control to Teens 3
Hudson Drill hand drill....
Hudson Brace, snap lock chuck....
Binocular operation microscope with innovative mechanism for smooth operation....
... has pioneered the development of ... system, an innovative solution that ... efficient and less invasive. The ... the OME-7000 surgical microscope, the ...
Medicine Products: